<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01165853</url>
  </required_header>
  <id_info>
    <org_study_id>200412368</org_study_id>
    <secondary_id>R01HL075675</secondary_id>
    <nct_id>NCT01165853</nct_id>
  </id_info>
  <brief_title>Effects of Consuming Sugar-Sweetened Beverages With Meals for 10 Weeks</brief_title>
  <acronym>IPOP</acronym>
  <official_title>Effects of Consuming Sugar-Sweetened Beverages With Meals for 10 Weeks on Hormones and Lipids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is compare the effects of consuming glucose- and fructose-sweetened&#xD;
      beverages on appetite, body weight, body fat, and the amount of energy the body burns as well&#xD;
      as effects on blood pressure, hormones, blood triglycerides and cholesterol, and the body's&#xD;
      sensitivity to the insulin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as a prospective, blinded diet intervention study during which the&#xD;
      participants consume either fructose- or glucose-sweetened beverages (25% of energy) with&#xD;
      meals. Experimental procedures, including 24-hour serial blood sampling, 26-h stable isotoped&#xD;
      infusions, post-heparin blood collection, gluteal biopsies, metabolic rate monitoring,&#xD;
      computed tomography scans of the abdomen, and Oral Glucose Tolerance and Disposal Tests, are&#xD;
      performed during baseline and at the end of a 10-week intervention period at the UC Davis&#xD;
      School of Medicine/Sacramento Veterans Affairs Medical Center Clinical Research Center&#xD;
      (CCRC). During the 2-week inpatient baseline period, subjects are served energy balanced&#xD;
      diets containing 15% of energy as protein, 30% as fat, and 55% as complex carbohydrate.&#xD;
      Following the baseline period, the subjects reside at home for 8 weeks and consume their&#xD;
      usual ad libitum diet along with 25% of energy requirements as fructose- or glucose-sweetened&#xD;
      beverages. Subjects then return to the CCRC for the 2-week inpatient intervention period at&#xD;
      the end of the study and are served energy-balanced diets containing 15% of energy as&#xD;
      protein, 30% as fat, 30% as complex carbohydrate and 25% of energy as fructose- or&#xD;
      glucose-sweetened beverage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour triglyceride area under the curve</measure>
    <time_frame>Baseline and 8-week intervention</time_frame>
    <description>32 serial blood samples are collected over a 24 hour period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity index</measure>
    <time_frame>Baseline and 8-week intervention</time_frame>
    <description>Insulin sensitivity is assessed using the deuterated glucose disposal method.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Insulin Resistance</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Glucose</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fructose</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose</intervention_name>
    <description>25% dose at 8-week intervention assigned to subjects.</description>
    <arm_group_label>Glucose</arm_group_label>
    <other_name>sugar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fructose</intervention_name>
    <description>25% dose at 8-week intervention assigned to subjects.</description>
    <arm_group_label>Fructose</arm_group_label>
    <other_name>sugar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Self-report of stable body weight&#xD;
&#xD;
          -  Women were post-menopausal based on a self-report of no menstruation for at least one&#xD;
             year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  evidence of diabetes&#xD;
&#xD;
          -  renal or hepatic disease&#xD;
&#xD;
          -  fasting serum TG concentrations &gt;400 mg/dl&#xD;
&#xD;
          -  hypertension (&gt;140/90 mg Hg)&#xD;
&#xD;
          -  surgery for weight loss&#xD;
&#xD;
          -  individuals who smoked&#xD;
&#xD;
          -  reported exercise of more than 3.5 hours/week at a level more vigorous than walking&#xD;
&#xD;
          -  having used thyroid, lipid-lowering, glucose-lowering, anti-hypertensive,&#xD;
             anti-depressant, or weight loss medications&#xD;
&#xD;
          -  habitual ingestion of more than one sugar-sweetened beverage/day or more than two&#xD;
             alcoholic beverages/day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J Havel, D.V.M.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kimber L Stanhope, Ph.D, R.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>July 16, 2010</study_first_submitted>
  <study_first_submitted_qc>July 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2010</study_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

